Antibody-urease conjugates for therapeutic purposes

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11931422
APP PUB NO 20180000963A1
SERIAL NO

15545549

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Pharmaceutical compositions comprising antibody-urease conjugates and substantially free of unconjugated urease are disclosed. These compositions are prepared by a method that does not require chromatographic purification. These pharmaceutical compositions have utility in the treatment of cancer by antibody-directed enzyme prodrug therapy wherein the urease converts endogenous urea into ammonia in situ to induce cytotoxicity.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • HELIX BIOPHARMA CORPORATION

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Chao, Heman Aurora, CA 9 221
Gaspar, Kimberly Jayne Saskatoon, CA 2 1
Kumar, Praveen Saskatoon, CA 97 1147
Tian, Baomin Edmonton, CA 12 224
Wong, Wah Yau Edmonton, CA 9 6

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Sep 19, 2027
7.5 Year Payment $3600.00 $1800.00 $900.00 Sep 19, 2031
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 19, 2035
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00